Positive Report for Raffles Medical Group (RAFLF) from DBS
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2025
0mins
Source: Business Insider
Analyst Upgrade: DBS analyst Rachel Tan upgraded Raffles Medical Group to a Buy with a price target of S$1.12, while the current consensus is a Moderate Buy at an average target of $0.84.
Insider Activity: Positive corporate insider sentiment has been observed, with 59 insiders increasing their share purchases compared to earlier this year.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
